Grant ID | RP240501 |
Awarded On | August 21, 2024 |
Title | Delivering Immunotherapy more effectively to glioblastoma with a "magnetic switch" |
Program | Academic Research |
Award Mechanism | High Impact/High Risk |
Institution/Organization | The University of Texas at Dallas |
Principal Investigator/Program Director | Zhenpeng Qin |
Cancer Sites | Brain and Other Nervous System |
Contracted Amount | $250,000 |
Lay Summary |
Glioblastoma, the most common adult brain tumor, is among the deadliest of all solid tumors with a median survival of 14.6 months. This status has not changed for over ten years despite intense therapeutic efforts. A unique and major challenge in treating brain tumors is the difficulty in delivering effective drugs across the blood-brain barrier (BBB), which protects the brain by preventing many substances in the blood from entering the brain tissue. This is also the case for antibodies that target immune checkpoints, in which the CNS penetration is limited. The main goal of this research is to invent a magnetic switch that can open up this barrier and let the medicine through, named as Mag... |